News
Patients with RA on rituximab at risk for worse COVID-19 outcomes
Risk mitigation strategies such as social distancing and wearing masks, especially indoors, remain important for people being treated with...
News
GRAPPA refines recommendations on psoriatic disease treatment
Biosimilars, Janus kinase inhibitors, and interleukin-23 inhibitors will feature in the 2021 update.
News
BEAT-LUPUS: Belimumab after rituximab delays severe flares
Results from a phase 2b trial are “clearly encouraging” and “support the hypothesis that BAFF [B-cell–activating factor] can drive flares after...
News
EULAR COVID-19 recommendations set for update
Conclusions drawn from a systematic literature review largely appear to reinforce the recommendations that have already been made but need further...
News
Rituximab’s serious infection risk in ANCA-vasculitis allayed by antibiotic use
Co-use of co-trimoxazole decreased the risk for infection, which remains high in patients with vasculitis who are treated with rituximab.
News
Multiple studies highlight pandemic’s impact on patients with rheumatic disease
From the Europe-based REUMAVID study to the United Kingdom’s CONTAIN study, some common themes are emerging, with lessons to be learned for future...
News
Baricitinib continuation rate high in real-world practice
Almost 75% of patients continued treatment at 6 months, and updated safety findings from the baricitinib clinical development program show no new...
News
Rituximab benefits seen in neuropsychiatric lupus
Findings from the largest prospective study of rituximab for NPSLE to date show signs of rituximab’s efficacy in reducing neuropsychiatric disease...
News
Line of therapy matters for assessing biologic’s serious infection risk in RA
The risk for serious infection seen with tocilizumab is confounded by whether the drug is given as first-line or as subsequent treatment in the...
News
Phage-targeting PCR test picks up early Lyme disease
Promising data show that detecting a viral gene in Lyme disease–causing bacteria can distinguish between early and late infection.